Just be a little careful here.  Although Dr. Spratt did an amazing analysis and thorough presentation of the subgroups, one shouldn't look at PSA <=0.6 as a "cutoff".  As Dr. Spratt pointed out in his presentation, the population on RTOG 9601 was mixed in terms of prognostic features..&...

Based on the RTOG 9601 original report and the secondary analysis presented at ASTRO this year, there is an overall survival benefit for men at PSAs >0.6 ng/mL. Thus, the standard of care for this population is to offer ADT. The optimal duration and agent(s) to use have not been formall...